Osteomyelitis Antibiotics Revenue and Competitors
Estimated Revenue & Valuation
- Osteomyelitis Antibiotics's estimated annual revenue is currently $75.6M per year.
- Osteomyelitis Antibiotics's estimated revenue per employee is $251,000
Employee Data
- Osteomyelitis Antibiotics has 301 Employees.
- Osteomyelitis Antibiotics grew their employee count by 9% last year.
Osteomyelitis Antibiotics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Marketing Specialist | Reveal Email/Phone |
Osteomyelitis Antibiotics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Osteomyelitis Antibiotics?
Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.
keywords:N/A
N/A
Total Funding
301
Number of Employees
$75.6M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Osteomyelitis Antibiotics News
The report aims is to provide useful information on the antibiotic selection and treatment suggestions to be followed for bone infections caused...
The intravenous antibiotic was changed to a broader spectrum (piperacillin-tazobactam) to cover the classical necrotizing otitis externa...
modestum infection in humans. We were able to successfully treat this patient using antibiotics alone in accordance with the EUCAST breakpoint...